We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • GLP-1 receptor agonist

    Health

    Survey Reveals American Perceptions of Weight-Loss Drugs and Their Impact on Obesity

    A recent Pew Research Center survey reveals Americans’ perceptions of weight-loss drugs like Ozempic and Wegovy, with 53% believing they are viable options for individuals with obesity. Despite high demand and supply shortages, only 16% of respondents expect these drugs to significantly reduce obesity in the U.S.

    Posted on Jhon
    Health

    New Study Shows Ozempic and Semaglutide May Lower Risk of Severe Liver Diseases

    A nationwide study in Sweden suggests that GLP1 agonists like Ozempic could lower the risk of cirrhosis and liver cancer in individuals with type 2 diabetes and chronic liver disease. This new finding provides a potential life-saving benefit of these medications, offering a new treatment option for preventing severe liver diseases.

    Posted on Jhon
    Health

    Obesity Drugs’ Superpower: Taming Inflammation

    Obesity drugs have another superpower: taming inflammation The latest generation of anti-obesity drugs has taken the world by storm, thanks to their effectiveness at treating diabetes and reducing weight. But these drugs also have a less well-known superpower: the ability…

    Posted on Jhon
    Health

    Semaglutide: A Revolutionary GLP-1 Receptor Agonist

    Semaglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor, has been making waves in the field of experimental studies, with researchers touting it as a revolutionary compound. The modest 30 amino acid incretin hormone, GLP-1, has shown significant activity, particularly…

    Posted on Jhon
    Health

    Diabetes Drug Shows Promise in Protecting Against Colorectal Cancer

    A recent analysis by researchers in the US suggests that a drug commonly used to treat type 2 diabetes could also be effective in protecting against colorectal cancer (CRC). The drug, known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), has…

    Posted on Jhon
    Health

    Tirzepatide vs. Semaglutide: A Comparison

    There has been a lot of buzz in the weight loss space with the emergence of medications like tirzepatide and semaglutide. But what’s the deal with tirzepatide vs. semaglutide? Let’s dive into the details. At a basic level, tirzepatide, also…

    Posted on Jhon